Vascular endothelial growth factor-induced nitric oxide-and PGI 2-dependent relaxation in human internal mammary arteries: A comparative study with KDR and Flt-1 selective mutants

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 5, 2004, Pages 615-621

  Wei, Wei ^a   Jin, Hongkui ^b   Chen, Zhi Wu ^a   Zioncheck, Thomas F ^b   Yim, Anthony P C ^c   He, Guo Wei ^a,c,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b GENENTECH INC   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Endothelium; Endothelium derived hyperpolarizing factor; Internal mammary artery; Nitric oxide; Prostacyclin; VEGF

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; INDOMETACIN; N(G) NITROARGININE; NITRIC OXIDE; PLACENTAL GROWTH FACTOR; PROSTACYCLIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; HYPERPOLARIZATION; IN VITRO STUDY; INTERNAL MAMMARY ARTERY; MALE; PRIORITY JOURNAL; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; EPOPROSTENOL; FEMALE; HUMANS; INDOMETHACIN; MALE; MAMMARY ARTERIES; MIDDLE AGED; NITRIC OXIDE; NITROARGININE; OXYHEMOGLOBINS; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS; VASODILATION;

EID: 7444262738     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200411000-00016     Document Type: Article

References (36)

1. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
2. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56:794-814.
3. Pearlman JD, Hibberd MG, Chuang ML, et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med. 1995;1:1085-1089.
4. Pu LQ, Sniderman AD, Brassard R, et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation. 1993;88:208-215.
5. Ku DD, Zaleski JK, Liu SY, et al. Vascular endothelial growth factor induced EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993;256:H586-H592.
6. Horowitz JR, Rivard A, Van der Zee R, et al. Vascular endothelial growth factor produces nitric oxide-dependent hypotension: evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997;17:2793-2800.
7. Yang RH, Thomas G, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamic and cardiac performance. J Cardiovasc Pharmacol. 1996;27:838-844.
8. Yang R, Bunting S, Ko A, et al. Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared to bolus injection. J Pharmacol Exp Ther. 1998;284:103-110.
9. Horowitz J, Hariawala M, Sheriff DD, et al. In vivo administration of vascular endothelial growth factor is associated with EDRF-dependent decrease in systemic hypotension in porcine and rabbit. Circulation 1995; 92:1-630
10. Lopez JJ, Laham RJ, Carrozza JP, et al. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol. 1997;273:H1317-H1323.
11. Tilton RG, Chang KC, Lejeune WS, et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci. 1999;40:689-696.
12. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49:568-581.
13. Liu MH, Jin H, Floten HS, et al. Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2001;296:473-477.
14. Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res. 1996;63:77-82.
15. Bauters C, Asahara T, Zheng LP, et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg. 1995;21:314-325.
16. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70.
17. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995; 376:62-66.
18. Li B, Fuh G, Meng G, et al. Receptor-selective variant of human vascular endothelial growth factor: Generation and characterization. J Biol Chem. 2000;275:29823-29828.
19. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). J Biol Chem. 2001;276:3222-3230.
20. Shen BQ, Lee DY, Cortopassi KM, et al. Vascular endothelial growth factor governs endothelial nitric-oxide synthase via a KDR/Flk-1 receptor and a protein kinase pathway. J Biol Chem. 1999;274:33057-33063.
21. Li B, Ogasawaral AK, Yang RH, et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension. 2002; 39:1095-1100.
22. He GW, Angus JA, Rosenfeldt FL. Reactivity of the canine isolated internal mammary artery, saphenous vein, and coronary artery to constrictor and dilator substances: relevance to coronary bypass graft surgery. J Cardiovasc Pharmacol. 1988;12:12-22.
23. He GW, Rosenfeldt FL, Buxton BF, et al. Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Implications for treatment of internal mammary artery spasm. Circulation. 1989;80:1141-1150.
24. Wei W, Floten HS, He GW. Interaction between vasodilators and vasopressin in internal mammary artery and clinical significance. Ann Thorac Surg. 2002;73:516-522.
25. Couffinhal T, Kearney M, Witzenbichler B, et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol. 1997;150:1673-1685.
26. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA. 1991;88:9267-9271.
27. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 1994; 269:25646-25654.
28. Ashrafpour H, Huang N, Neligan PC, et al. Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature. Am J Physiol Heart Circ Physiol. 2004;286:H946-H954.
29. Ge ZD, Zhang XH, Fung PC, et al. Endothelium-dependent hyperpolarization and relaxation resistance to N(G)-nitro-L-arginine and indomethacin in coronary circulation. Cardiovasc Res. 2000;46:547-556.
30. Liu ZG, Ge ZD, He GW. Difference in endothelium-derived hyperpolarizing factor-mediated hyperpolarization and nitric oxide release between human internal mammary artery and saphenous vein. Circulation. 2000;102(19 Suppl 3):296-301.
31. He GW, Liu ZG. Comparison of nitric oxide release and endothelium-derived hyperpolarizing factor-mediated hyperpolarization between human radial and internal mammary arteries. Circulation. 2001;104(12 Suppl 1):344-349.
32. Oemar BS, Tschudi MR, Godoy N, et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998;97:2494-2498.
33. FitzGerald GA, Smith B, Pedersen AK, et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984;310:1065-1068.
34. He H, Venema VJ, Gu X, et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem. 1999;274:25130-25135.
35. Murohara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 1998;97:99-107.
36. LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science. 2003;299:890-893.